Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.

Journal of gastrointestinal cancer - 1 Mar 2021

Xavier Camila B, Marchetti Katia R, Castria Tiago B, Jardim Denis L F, Fernandes Gustavo S

Abstract excerpt

PURPOSE: Over the last decades, cytotoxic chemotherapy has been the cornerstone of metastatic pancreatic adenocarcinoma treatment. In late-stage disease, a range of treatment regimens still offers minor benefits. Molecular profiling studies have shown that pancreatic adenocarcinoma (PDAC) is a mutation-driven tumor type, with KRAS mutations found in approximately 90% of cases, which could partially explain the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to CA-19-9 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Hydroxychloroquine

Share to Pancreas

Share to Positron Emission Tomography Computed Tomography

Share to Pyridones

Share to Pyrimidinones

Source

Identifiers

PMID: 33225411
DOI: 10.1007/s12029-020-00556-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.PMID 33225411Read ↗

A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted Therapy for BRAF V600E Positive Pancreatic Adenocarcinoma: Two Case Reports.Semantic proximity Read ↗

Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies.Semantic proximity Read ↗

Clinical trial results show promise of targeting autophagy BRAF mutant melanoma.Semantic proximity Read ↗

Computational-experimental repurposing reveals synergistic sorafenib/hydroxychloroquine response in KRAS-mutant breast cancer.Semantic proximity Read ↗

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.Semantic proximity Read ↗

Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report.Semantic proximity Read ↗

Hydroxychloroquine Synergizes With The PI3K Inhibitor BKM120 to Exhibit Antitumor Efficacy Independent of AutophagySemantic proximity Read ↗

SMAD4 Loss is Associated with Response to Neoadjuvant Chemotherapy with Hydroxychloroquine in Patients with Pancreatic AdenocarcinomaSemantic proximity Read ↗

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma: a real-world studySemantic proximity Read ↗

Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.Semantic proximity Read ↗

ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.